[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618054":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":20,"eligibilityCriteria":37,"healthyVolunteers":34,"sex":38,"minAge":39,"maxAge":20,"enrollmentInfo":40,"targetDuration":20,"studyType":43,"phases":44,"briefSummary":18,"conditions":46,"keywords":20,"overallStatus":49,"whyStopped":20,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":20},{"fullName":5,"class":6},"College of Physicians and Surgeons Pakistan","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Finerenone Group","EXPERIMENTAL","Finerenone Drug",[13],"Drug: Finerenone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Finerenone","To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Muhammad Awais Danish, FCPS (Internal Medicine)","CONTACT","923037589797","raoawaisdanish@gmail.com",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":31,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Muhammad Awais Danish","Dr","Nishtar Medical University","100618054","finerenone-for-cardiorenal-protection-in-diabetic-ckd-impact-on-renal-function-decline-and-heart-failure-100618054",false,"NCT07326631","Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosed cases of type 2 diabetes mellitus.\n* Chronic kidney disease with eGFR 25-90 mL\u002Fmin\u002F1.73m² and\u002For UACR ≥30 mg\u002Fg.\n* On stable ACE inhibitor or ARB therapy for at least 4 weeks.\n* Serum potassium ≤4.8 mmol\u002FL.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Symptomatic heart failure (NYHA class II-IV).\n* eGFR \\\u003C25 mL\u002Fmin\u002F1.73m² or on maintenance dialysis.\n* Known non-diabetic kidney disease.\n* Recent major cardiovascular event (within 30 days).\n* Serum potassium \\>4.8 mmol\u002FL or history of severe hyperkalaemia.\n* Contraindication or hypersensitivity to finerenone.\n* Pregnancy or lactation.\n* Any condition limiting compliance or follow-up.","ALL","18 Years",{"count":41,"type":42},120,"ESTIMATED","INTERVENTIONAL",[45],"NA",[47,48],"Diabetic Kidney Disease (DKD)","Heart Failure","NOT_YET_RECRUITING","2025-12-24",{"date":52,"type":53},"2026-01-08","ACTUAL",{"date":55,"type":42},"2026-01-01",{"date":57,"type":42},"2026-07-01",{"name":5,"class":6}]